

S Moein Moghimi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7581674/s-moein-moghimi-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

206
papers

16,801
citations

61
h-index

126
g-index

236
ext. papers

18,375
ext. citations

8.6
avg, IF

6.99
L-index

#	Paper	IF	Citations
206	Cell medium-dependent dynamic modulation of size and structural transformations of binary phospholipid/β fatty acid liquid crystalline nano-self-assemblies: Implications in interpretation of cell uptake studies. <i>Journal of Colloid and Interface Science</i> , 2022 , 606, 464-479	9.3	2
205	Critical issues and pitfalls in serum and plasma handling for complement analysis in nanomedicine and bionanotechnology. <i>Nano Today</i> , 2022 , 44, 101479	17.9	1
204	Roadmap on nanomedicine. <i>Nanotechnology</i> , 2021 , 32, 012001	3.4	5
203	Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines. <i>Molecular Therapy</i> , 2021 , 29, 898-907	10.7	29
202	Integrin-Targeted, Short Interfering RNA Nanocomplexes for Neuroblastoma Tumor-Specific Delivery Achieve MYCN Silencing with Improved Survival. <i>Advanced Functional Materials</i> , 2021 , 31, 2104843	15.6	4
201	A structurally diverse library of glycerol monooleate/oleic acid non-lamellar liquid crystalline nanodispersions stabilized with nonionic methoxypoly(ethylene glycol) (mPEG)-lipids showing variable complement activation properties. <i>Journal of Colloid and Interface Science</i> , 2021 , 582, 906-917	9.3	12
200	Dendrimer end-terminal motif-dependent evasion of human complement and complement activation through IgM hitchhiking. <i>Nature Communications</i> , 2021 , 12, 4858	17.4	2
199	Microneedle-based devices for point-of-care infectious disease diagnostics. <i>Acta Pharmaceutica Sinica B</i> , 2021 , 11, 2344-2361	15.5	11
198	Complement opsonization of nanoparticles: Differences between humans and preclinical species. <i>Journal of Controlled Release</i> , 2021 , 338, 548-556	11.7	7
197	Complement activation by drug carriers and particulate pharmaceuticals: Principles, challenges and opportunities. <i>Advanced Drug Delivery Reviews</i> , 2020 , 157, 83-95	18.5	21
196	Hexosome engineering for targeting of regional lymph nodes. <i>Materialia</i> , 2020 , 11, 100705	3.2	8
195	Overcoming Nanoparticle-Mediated Complement Activation by Surface PEG Pairing. <i>Nano Letters</i> , 2020 , 20, 4312-4321	11.5	34
194	Complement Activation by Nanomaterials. <i>Molecular and Integrative Toxicology</i> , 2020 , 83-98	0.5	3
193	Airborne Particulate Matter and SARS-CoV-2 Partnership: Virus Hitchhiking, Stabilization and Immune Cell Targeting - A Hypothesis. <i>Frontiers in Immunology</i> , 2020 , 11, 579352	8.4	8
192	CAR T-cell bioengineering: Single variable domain of heavy chain antibody targeted CARs. <i>Advanced Drug Delivery Reviews</i> , 2019 , 141, 41-46	18.5	16
191	Determination of Polycation-Mediated Perturbation of Mitochondrial Respiration in Intact Cells by High-Resolution Respirometry (Oxygraph-2k, OROBOROS). <i>Methods in Molecular Biology</i> , 2019 , 1943, 313-322	1.4	5
190	Lactate Dehydrogenase Assay for Assessment of Polycation Cytotoxicity. <i>Methods in Molecular Biology</i> , 2019 , 1943, 291-299	1.4	9

189	Combined Fluorimetric Caspase-3/7 Assay and Bradford Protein Determination for Assessment of Polycation-Mediated Cytotoxicity. <i>Methods in Molecular Biology</i> , 2019 , 1943, 301-311	1.4	
188	Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55. <i>Journal of Controlled Release</i> , 2019 , 302, 181-189	11.7	14
187	The Interplay Between Blood Proteins, Complement, and Macrophages on Nanomedicine Performance and Responses. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019 , 370, 581-592	4.7	35
186	Perturbation of mitochondrial bioenergetics by polycations counteracts resistance to BRAF inhibition in melanoma cells. <i>Journal of Controlled Release</i> , 2019 , 309, 158-172	11.7	1
185	On the issue of transparency and reproducibility in nanomedicine. <i>Nature Nanotechnology</i> , 2019 , 14, 629-635	28.7	92
184	Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide. <i>Nature Communications</i> , 2019 , 10, 4635	17.4	52
183	Non-Lamellar Liquid Crystalline Nanocarriers for Thymoquinone Encapsulation. <i>Molecules</i> , 2019 , 25,	4.8	15
182	Pharmacokinetic analysis reveals limitations and opportunities for nanomedicine targeting of endothelial and extravascular compartments of tumours. <i>Journal of Drug Targeting</i> , 2019 , 27, 690-698	5.4	12
181	Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles. <i>Nature Nanotechnology</i> , 2019 , 14, 260-268	28.7	130
180	Multivalent targeting and killing of HER2 overexpressing breast carcinoma cells with methotrexate-encapsulated tetra-specific non-overlapping variable domain heavy chain anti-HER2 antibody-PEG-liposomes: In vitro proof-of-concept. <i>European Journal of Pharmaceutical Sciences</i> , 2018 , 122, 42-50	5.1	18
179	Nanoparticle transport pathways into tumors. <i>Journal of Nanoparticle Research</i> , 2018 , 20, 169	2.3	38
178	C1q-Mediated Complement Activation and C3 Opsonization Trigger Recognition of Stealth Poly(2-methyl-2-oxazoline)-Coated Silica Nanoparticles by Human Phagocytes. <i>ACS Nano</i> , 2018 , 12, 5834-5847	16.7	58
177	Skin Biosensing and Bioanalysis: what the Future Holds. <i>Precision Nanomedicine</i> , 2018 , 1, 124-127	1.2	1
176	Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection/infusion reactions. <i>Drug Discovery Today</i> , 2018 , 23, 1034-1042	8.8	44
175	Translational gaps in animal models of human infusion reactions to nanomedicines. <i>Nanomedicine</i> , 2018 , 13, 973-975	5.6	19
174	Cisplatin Encapsulation Generates Morphologically Different Multicompartment in the Internal Nanostructures of Nonlamellar Liquid-Crystalline Self-Assemblies. <i>Langmuir</i> , 2018 , 34, 6570-6581	4	25
173	Smart polymers in drug delivery: a biological perspective. <i>Polymer Chemistry</i> , 2017 , 8, 41-51	4.9	45
172	Peptide and nucleic acid-directed self-assembly of cationic nanovehicles through giant unilamellar vesicle modification: Targetable nanocomplexes for in vivo nucleic acid delivery. <i>Acta Biomaterialia</i> , 2017 , 51, 351-362	10.8	23

171	Polyplex Evolution: Understanding Biology, Optimizing Performance. <i>Molecular Therapy</i> , 2017 , 25, 1476-1490	14.90	102
170	Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes. <i>Nature Nanotechnology</i> , 2017 , 12, 589-594	28.7	121
169	Complement activation turnover on surfaces of nanoparticles. <i>Nano Today</i> , 2017 , 15, 8-10	17.9	51
168	Poly-(amidoamine) dendrimers with a precisely core positioned sulforhodamine B molecule for comparative biological tracing and profiling. <i>Journal of Controlled Release</i> , 2017 , 246, 88-97	11.7	17
167	Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. <i>Nature Nanotechnology</i> , 2017 , 12, 387-393	28.7	299
166	Revealing Dynamics of Accumulation of Systemically Injected Liposomes in the Skin by Intravital Microscopy. <i>ACS Nano</i> , 2017 , 11, 11584-11593	16.7	17
165	Interaction of extremophilic archaeal viruses with human and mouse complement system and viral biodistribution in mice. <i>Molecular Immunology</i> , 2017 , 90, 273-279	4.3	4
164	Nanoparticles and innate immunity: new perspectives on host defence. <i>Seminars in Immunology</i> , 2017 , 34, 33-51	10.7	160
163	ImmunoPEGLiposome-mediated reduction of blood and brain amyloid levels in a mouse model of Alzheimer's disease is restricted to aged animals. <i>Biomaterials</i> , 2017 , 112, 141-152	15.6	24
162	and Differences in Murine Third Complement Component (C3) Opsonization and Macrophage/Leukocyte Responses to Antibody-Functionalized Iron Oxide Nanoworms. <i>Frontiers in Immunology</i> , 2017 , 8, 151	8.4	29
161	Platelet mimicry: The emperor's new clothes?. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016 , 12, 245-8	6	14
160	A structurally diverse library of safe-by-design citrem-phospholipid lamellar and non-lamellar liquid crystalline nano-assemblies. <i>Journal of Controlled Release</i> , 2016 , 239, 1-9	11.7	56
159	AFM visualization of sub-50nm polyplex disposition to the nuclear pore complex without compromising the integrity of the nuclear envelope. <i>Journal of Controlled Release</i> , 2016 , 244, 24-29	11.7	13
158	The Art of Complement: Complement Sensing of Nanoparticles and Consequences. <i>Advances in Delivery Science and Technology</i> , 2016 , 43-51		3
157	Soluble and immobilized graphene oxide activates complement system differently dependent on surface oxidation state. <i>Biomaterials</i> , 2016 , 78, 20-6	15.6	32
156	Complement Propriety and Conspiracy in Nanomedicine: Perspective and a Hypothesis. <i>Nucleic Acid Therapeutics</i> , 2016 , 26, 67-72	4.8	12
155	An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil [®] , Caelyx [®] , DOXOrubicin, and SinaDoxosome. <i>Journal of Controlled Release</i> , 2016 , 221, 1-8	11.7	122
154	Activation of Human Complement System by Dextran-Coated Iron Oxide Nanoparticles Is Not Affected by Dextran/Fe Ratio, Hydroxyl Modifications, and Crosslinking. <i>Frontiers in Immunology</i> , 2016 , 7, 418	8.4	36

153	Recognition of extremophilic archaeal viruses by eukaryotic cells: a promising nanoplatform from the third domain of life. <i>Scientific Reports</i> , 2016 , 6, 37966	4.9	4
152	Differential Modulation of Cellular Bioenergetics by Poly(L-lysine)s of Different Molecular Weights. <i>Biomacromolecules</i> , 2015 , 16, 2119-26	6.9	16
151	New platforms for multi-functional ocular lenses: engineering double-sided functionalized nano-coatings. <i>Journal of Drug Targeting</i> , 2015 , 23, 305-10	5.4	15
150	Citrem modulates internal nanostructure of glyceryl monooleate dispersions and bypasses complement activation: Towards development of safe tunable intravenous lipid nanocarriers. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015 , 11, 1909-14	6	49
149	Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake. <i>ACS Nano</i> , 2015 , 9, 10758-68	16.7	69
148	Repeated intraperitoneal injections of liposomes containing phosphatidic acid and cardiolipin reduce amyloid- β levels in APP/PS1 transgenic mice. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015 , 11, 421-30	6	51
147	Tumour exosomes display differential mechanical and complement activation properties dependent on malignant state: implications in endothelial leakiness. <i>Journal of Extracellular Vesicles</i> , 2015 , 4, 29685	16.4	69
146	Insidious pathogen-mimicking properties of nanoparticles in triggering the lectin pathway of the complement system. <i>European Journal of Nanomedicine</i> , 2015 , 7,		5
145	Modulatory effect of human plasma on the internal nanostructure and size characteristics of liquid-crystalline nanocarriers. <i>Langmuir</i> , 2015 , 31, 5042-9	4	48
144	Cubosomes and hexosomes as versatile platforms for drug delivery. <i>Therapeutic Delivery</i> , 2015 , 6, 1347-64	9.8	105
143	Polyethylenimine architecture-dependent metabolic imprints and perturbation of cellular redox homeostasis. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2015 , 1847, 328-342	4.6	26
142	Dendrimers in Medicine: Therapeutic Concepts and Pharmaceutical Challenges. <i>Bioconjugate Chemistry</i> , 2015 , 26, 1198-211	6.3	161
141	Recent Advances in Cryo-TEM Imaging of Soft Lipid Nanoparticles. <i>AIMS Biophysics</i> , 2015 , 2, 116-130	0.8	39
140	Cancer nanomedicine and the complement system activation paradigm: anaphylaxis and tumour growth. <i>Journal of Controlled Release</i> , 2014 , 190, 556-62	11.7	69
139	Nanoparticles in Medicine: Nanoparticle Engineering for Macrophage Targeting and Nanoparticles that Avoid Macrophage Recognition 2014 , 77-89		3
138	T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2014 , 1840, 378-86	4	47
137	Live-cell fluorescent microscopy platforms for real-time monitoring of polyplex-cell interaction: basic guidelines. <i>Methods</i> , 2014 , 68, 300-7	4.6	8
136	Just so stories: the random acts of anti-cancer nanomedicine performance. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014 , 10, 1661-6	6	57

135	The Role of Complement in Antibody Therapy for Infectious Diseases. <i>Microbiology Spectrum</i> , 2014 , 2,	8.9	5
134	Anatomical and Physicochemical Factors Controlling Nanoparticle Pharmacokinetics. <i>Frontiers in Nanobiomedical Research</i> , 2014 , 31-44		1
133	Polycation-mediated integrated cell death processes. <i>Advances in Genetics</i> , 2014 , 88, 353-98	3.3	16
132	Poly(3-hydroxybutyrate-co-R-3-hydroxyhexanoate) nanoparticles with polyethylenimine coat as simple, safe, and versatile vehicles for cell targeting: population characteristics, cell uptake, and intracellular trafficking. <i>Advanced Healthcare Materials</i> , 2014 , 3, 817-24	10.1	36
131	Mechanisms of complement activation by dextran-coated superparamagnetic iron oxide (SPIO) nanoworms in mouse versus human serum. <i>Particle and Fibre Toxicology</i> , 2014 , 11, 64	8.4	69
130	Reciprocity in the developmental regulation of aquaporins 1, 3 and 5 during pregnancy and lactation in the rat. <i>PLoS ONE</i> , 2014 , 9, e106809	3.7	8
129	Defining and characterizing non-biological complex drugs (NBCDs) [Is size enough? The case for liposomal doxorubicin generics (liposomal nanosimilars)]for injection. <i>GAJI Journal</i> , 2014 , 3, 56-57	3.1	5
128	Uptake and Intracellular Trafficking of Nanocarriers. <i>Fundamental Biomedical Technologies</i> , 2014 , 117-138		2
127	High resolution respirometry analysis of polyethylenimine-mediated mitochondrial energy crisis and cellular stress: Mitochondrial proton leak and inhibition of the electron transport system. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2013 , 1827, 1213-25	4.6	51
126	Nanomedicine and the complement paradigm. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2013 , 9, 458-60	6	59
125	Complement monitoring of Pluronic 127 gel and micelles: suppression of copolymer-mediated complement activation by elevated serum levels of HDL, LDL, and apolipoproteins AI and B-100. <i>Journal of Controlled Release</i> , 2013 , 170, 167-74	11.7	37
124	Surfactant-mediated complement activation in beagle dogs. <i>International Immunopharmacology</i> , 2013 , 17, 33-4	5.8	7
123	Lactate dehydrogenase assay for assessment of polycation cytotoxicity. <i>Methods in Molecular Biology</i> , 2013 , 948, 13-22	1.4	26
122	Structural profiling and biological performance of phospholipid-hyaluronan functionalized single-walled carbon nanotubes. <i>Journal of Controlled Release</i> , 2013 , 170, 295-305	11.7	21
121	Single-walled carbon nanotube surface control of complement recognition and activation. <i>ACS Nano</i> , 2013 , 7, 1108-19	16.7	100
120	Complement activation by PEG-functionalized multi-walled carbon nanotubes is independent of PEG molecular mass and surface density. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2013 , 9, 469-73	6	32
119	Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents. <i>Cancer Letters</i> , 2013 , 334, 237-44	9.9	45
118	Combined fluorimetric caspase 3/7 assay and bradford protein determination for assessment of polycation-mediated cytotoxicity. <i>Methods in Molecular Biology</i> , 2013 , 948, 23-33	1.4	1

117	The possible "proton sponge " effect of polyethylenimine (PEI) does not include change in lysosomal pH. <i>Molecular Therapy</i> , 2013 , 21, 149-57	11.7	494
116	Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer Therapy. <i>BiolImpacts</i> , 2013 , 3, 1-4	3.5	9
115	Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. <i>Oncotarget</i> , 2013 , 4, 584-99	3.3	133
114	Complement system and the brain: selected pathologies and avenues toward engineering of neurological nanomedicines. <i>Journal of Controlled Release</i> , 2012 , 161, 283-9	11.7	21
113	Total internal reflection fluorescence (TIRF) microscopy for real-time imaging of nanoparticle-cell plasma membrane interaction. <i>Methods in Molecular Biology</i> , 2012 , 906, 473-82	1.4	9
112	Complement Sensing of Nanoparticles and Nanomedicines. <i>ACS Symposium Series</i> , 2012 , 365-382	0.4	10
111	Particulate systems for targeting of macrophages: basic and therapeutic concepts. <i>Journal of Innate Immunity</i> , 2012 , 4, 509-28	6.9	53
110	Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2012 , 8 Suppl 1, S5-20	6	64
109	PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: toward engineering of functional nanomedicines for Alzheimer's disease. <i>ACS Nano</i> , 2012 , 6, 5897-908	16.7	141
108	Polyethylenimine-mediated impairment of mitochondrial membrane potential, respiration and membrane integrity: implications for nucleic acid delivery and gene therapy. <i>Mitochondrion</i> , 2012 , 12, 162-8	4.9	41
107	Perspectives on carbon nanotube-mediated adverse immune effects. <i>Advanced Drug Delivery Reviews</i> , 2012 , 64, 1700-5	18.5	46
106	Genomic perspectives in inter-individual adverse responses following nanomedicine administration: The way forward. <i>Advanced Drug Delivery Reviews</i> , 2012 , 64, 1385-93	18.5	34
105	Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective. <i>Maturitas</i> , 2012 , 73, 5-18	5	28
104	Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. <i>Annual Review of Pharmacology and Toxicology</i> , 2012 , 52, 481-503	17.9	409
103	Reshaping the future of nanopharmaceuticals: ad iudicium. <i>ACS Nano</i> , 2011 , 5, 8454-8	16.7	75
102	Transformation of structurally diverse steroidal analogues by the fungus <i>Corynespora cassiicola</i> CBS 161.60 results in generation of 8 β monohydroxylated metabolites with evidence in favour of 8 β hydroxylation through inverted binding in the 9 β hydroxylase. <i>Biochimica Et Biophysica Acta - Molecular and Cellular Sciences</i> , 2011 , 1811, 1051-61	5	8
101	Functionalization with ApoE-derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide. <i>Journal of Biotechnology</i> , 2011 , 156, 341-6	3.7	78
100	Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2011 , 7, 521-40	6	199

99	Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells. <i>Journal of Controlled Release</i> , 2011 , 156, 85-91	11.7	55
98	Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. <i>Journal of Controlled Release</i> , 2011 , 156, 231-8	11.7	171
97	Biological targeting and innovative therapeutic interventions with phage-displayed peptides and structured nucleic acids (aptamers). <i>Current Opinion in Biotechnology</i> , 2011 , 22, 832-8	11.4	16
96	Material properties in complement activation. <i>Advanced Drug Delivery Reviews</i> , 2011 , 63, 1000-7	18.5	193
95	Complement monitoring of nanomedicines and implants. <i>Advanced Drug Delivery Reviews</i> , 2011 , 63, 963-8	18.5	3
94	Engineering liposomes and nanoparticles for biological targeting. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2011 , 125, 251-80	1.7	25
93	Complement monitoring of carbon nanotubes. <i>Nature Nanotechnology</i> , 2010 , 5, 382; author reply 382-3	28.7	22
92	Complement monitoring of carbon nanotubes. <i>Nature Nanotechnology</i> , 2010 , 5, 382-383	28.7	10
91	Polycation cytotoxicity: a delicate matter for nucleic acid therapy: focus on polyethylenimine. <i>Soft Matter</i> , 2010 , 6, 4001	3.6	173
90	Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. <i>ACS Nano</i> , 2010 , 4, 6629-38	16.7	235
89	Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead. <i>Journal of Controlled Release</i> , 2010 , 146, 175-81	11.7	142
88	Cationic carriers of genetic material and cell death: a mitochondrial tale. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2010 , 1797, 1203-9	4.6	102
87	Hypersensitivity Reactions to Nanomedicines: Causative Factors and Optimization of Design Parameters 2010 , 225-237		2
86	Chapter 3: Nanoparticle Engineering for the Lymphatic System and Lymph Node Targeting. <i>RSC Nanoscience and Nanotechnology</i> , 2010 , 81-97		2
85	Tunable 3D and 2D polystyrene nanoparticle assemblies using surface wettability, low volume fraction and surfactant effects. <i>Nanotechnology</i> , 2009 , 20, 025604	3.4	12
84	Complement-mediated tumour growth: implications for cancer nanotechnology and nanomedicines. <i>Molecular Immunology</i> , 2009 , 46, 1571-2	4.3	16
83	Factors Controlling Pharmacokinetics of Intravenously Injected Nanoparticulate Systems 2009 , 267-282		2
82	Liposome triggering of innate immune responses: a perspective on benefits and adverse reactions. <i>Journal of Liposome Research</i> , 2009 , 19, 85-90	6.1	81

81	Complement: alive and kicking nanomedicines. <i>Journal of Biomedical Nanotechnology</i> , 2009 , 5, 364-72	4	64
80	A special issue on nano- and micro-technologies for biological targeting, tracking, imaging and sensing. <i>Journal of Biomedical Nanotechnology</i> , 2009 , 5, 611-3	4	1
79	Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. <i>Molecular Immunology</i> , 2008 , 45, 3797-803	4.3	112
78	Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. <i>Molecular Immunology</i> , 2008 , 46, 225-32	4.3	197
77	Enhanced lymph node retention of subcutaneously injected IgG1-PEG2000-liposomes through pentameric IgM antibody-mediated vesicular aggregation. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2008 , 1778, 51-5	3.8	19
76	Lymphatic targeting of immuno-PEG-liposomes: evaluation of antibody-coupling procedures on lymph node macrophage uptake. <i>Journal of Drug Targeting</i> , 2008 , 16, 586-90	5.4	10
75	Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug. <i>Expert Opinion on Drug Delivery</i> , 2008 , 5, 205-19	8	29
74	Polymeric Nanocarriers for siRNA Delivery: Challenges and Future Prospects. <i>Journal of Biomedical Nanotechnology</i> , 2008 , 4, 258-275	4	24
73	Liposome-mediated triggering of complement cascade. <i>Journal of Liposome Research</i> , 2008 , 18, 195-209	6.1	57
72	Particulate nanomedicine in the footsteps of platelet homing. <i>Nanomedicine</i> , 2007 , 2, 381-4	5.6	1
71	Ordering of binary polymeric nanoparticles on hydrophobic surfaces assembled from low volume fraction dispersions. <i>Journal of the American Chemical Society</i> , 2007 , 129, 13390-1	16.4	32
70	Modification of the Stewart biphasic colorimetric assay for stable and accurate quantitative determination of Pluronic and Tetronic block copolymers for application in biological systems. <i>Analytical Biochemistry</i> , 2007 , 361, 287-93	3.1	19
69	Recent developments in polymeric nanoparticle engineering and their applications in experimental and clinical oncology. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2006 , 6, 553-561	2.2	55
68	Polymeric Nanoparticles as Drug Carriers and Controlled Release Implant Devices 2006 , 29-42		7
67	Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. <i>FASEB Journal</i> , 2006 , 20, 2591-3	0.9	169
66	Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption. <i>Journal of Nanoscience and Nanotechnology</i> , 2006 , 6, 3126-33	1.3	50
65	The effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG liposomes. <i>Biomaterials</i> , 2006 , 27, 136-44	15.6	64
64	Activation of the human complement system by cholesterol-rich and PEGylated liposomes-modulation of cholesterol-rich liposome-mediated complement activation by elevated serum LDL and HDL levels. <i>Journal of Liposome Research</i> , 2006 , 16, 167-74	6.1	51

63	Low and high molecular weight poly(L-lysine)s/poly(L-lysine)-DNA complexes initiate mitochondrial-mediated apoptosis differently. <i>FEBS Letters</i> , 2005 , 579, 6191-8	3.8	98
62	Nanomedicine: current status and future prospects. <i>FASEB Journal</i> , 2005 , 19, 311-30	0.9	1492
61	A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. <i>Molecular Therapy</i> , 2005 , 11, 990-5	11.7	875
60	Cellular distribution of nonionic micelles. <i>Science</i> , 2004 , 303, 626-8; author reply 626-8	33.3	56
59	Causative factors behind poloxamer 188 (Pluronic F68, Flcor)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2004 , 1689, 103-13	6.9	92
58	Synthetic polymers in 21st century therapeutics: the way forward. <i>Drug Discovery Today</i> , 2003 , 8, 154-6	8.8	4
57	Modulation of lymphatic distribution of subcutaneously injected poloxamer 407-coated nanospheres: the effect of the ethylene oxide chain configuration. <i>FEBS Letters</i> , 2003 , 540, 241-4	3.8	49
56	Real-time evidence of surface modification at polystyrene lattices by poloxamine 908 in the presence of serum: in vivo conversion of macrophage-prone nanoparticles to stealth entities by poloxamine 908. <i>FEBS Letters</i> , 2003 , 547, 177-82	3.8	26
55	Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. <i>Progress in Lipid Research</i> , 2003 , 42, 463-78	14.3	940
54	Nanoparticle-mediated gene delivery to tumour neovasculature. <i>Trends in Molecular Medicine</i> , 2003 , 9, 2-4	11.5	41
53	Endothelial cells as therapeutic targets in cancer: new biology and novel delivery systems. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2003 , 20, 139-52	2.8	14
52	Exploitation of Macrophage Clearance Functions In Vivo. <i>Handbook of Experimental Pharmacology</i> , 2003 , 41-54	3.2	4
51	Chemical camouflage of nanospheres with a poorly reactive surface: towards development of stealth and target-specific nanocarriers. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2002 , 1590, 131-9	4.9	77
50	Modulation of murine liver macrophage clearance of liposomes by diethylstilbestrol. The effect of vesicle surface charge and a role for the complement receptor Mac-1 (CD11b/CD18) of newly recruited macrophages in liposome recognition. <i>Journal of Controlled Release</i> , 2002 , 78, 55-65	11.7	29
49	Therapeutic synthetic polymers: a game of Russian roulette?. <i>Drug Discovery Today</i> , 2002 , 7, 998-1001	8.8	73
48	Liposome recognition by resident and newly recruited murine liver macrophages. <i>Journal of Liposome Research</i> , 2002 , 12, 67-70	6.1	6
47	PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance. <i>FEBS Letters</i> , 2002 , 532, 338-44	3.8	119
46	Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups. <i>Pharmaceutical Research</i> , 2001 , 18, 1-8	4.5	109

45	Recognition and clearance of methoxypoly(ethyleneglycol)2000-grafted liposomes by macrophages with enhanced phagocytic capacity. Implications in experimental and clinical oncology. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2001 , 1526, 227-9	4	21
44	Capture of Stealth Nanoparticles by the Body's Defences. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2001 , 18, 24	2.8	104
43	Long-circulating and target-specific nanoparticles: theory to practice. <i>Pharmacological Reviews</i> , 2001 , 53, 283-318	22.5	2324
42	Capture of stealth nanoparticles by the body's defences. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2001 , 18, 527-50	2.8	32
41	Recent advances in cellular, sub-cellular and molecular targeting. <i>Advanced Drug Delivery Reviews</i> , 2000 , 41, 129-33	18.5	36
40	Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. <i>Trends in Biotechnology</i> , 2000 , 18, 412-20	15.1	313
39	Hormonal Control of Macrophage Phagocytosis of Phospholipid Vesicles. <i>Journal of Liposome Research</i> , 2000 , 10, 409-417	6.1	1
38	Subcutaneous and intravenous delivery of diagnostic agents to the lymphatic system: applications in lymphoscintigraphy and indirect lymphography. <i>Advanced Drug Delivery Reviews</i> , 1999 , 37, 295-312	18.5	110
37	Re-establishing the long circulatory behaviour of poloxamine-coated particles after repeated intravenous administration: applications in cancer drug delivery and imaging. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1999 , 1472, 399-403	4	21
36	Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - The concept of tissue specificity. <i>Advanced Drug Delivery Reviews</i> , 1998 , 32, 45-60	18.5	187
35	Recent Developments and Limitations of Poloxamine-Coated Long-Circulating Particles in Experimental Drug Delivery 1998 , 263-274		
34	A single dose of intravenously injected poloxamine-coated long-circulating particles triggers macrophage clearance of subsequent doses in rats. <i>Clinical Science</i> , 1997 , 93, 371-9	6.5	49
33	Prolonging the circulation time and modifying the body distribution of intravenously injected polystyrene nanospheres by prior intravenous administration of poloxamine-908. A 'hepatic-blockade' event or manipulation of nanosphere surface in vivo?. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1997 , 1336, 1-6	4	33
32	Activation of the mononuclear phagocyte system by poloxamine 908: its implications for targeted drug delivery. <i>Pharmaceutical Research</i> , 1997 , 14, 1629-33	4.5	2
31	Altered tissue-specific opsonic activities and opsono-recognition of liposomes in tumour-bearing rats. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1996 , 1285, 56-64	3.8	9
30	Advanced colloid-based systems for efficient delivery of drugs and diagnostic agents to the lymphatic tissues. <i>Progress in Biophysics and Molecular Biology</i> , 1996 , 65, 221-49	4.7	48
29	Poloxamer-188 revisited: a potentially valuable immune modulator. <i>Journal of the National Cancer Institute</i> , 1996 , 88, 766-8	9.7	35
28	Mechanisms regulating body distribution of nanospheres conditioned with pluronic and tetronic block co-polymers. <i>Advanced Drug Delivery Reviews</i> , 1995 , 16, 183-193	18.5	62

27	Exploiting bone marrow microvascular structure for drug delivery and future therapies. <i>Advanced Drug Delivery Reviews</i> , 1995 , 17, 61-73	18.5	73
26	Mechanisms of splenic clearance of blood cells and particles: towards development of new splenotropic agents. <i>Advanced Drug Delivery Reviews</i> , 1995 , 17, 103-115	18.5	116
25	Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes. <i>FEBS Letters</i> , 1994 , 344, 25-30	3.8	106
24	Organ-Specific Targeting of Synthetic and Natural Drug Carriers. <i>Advances in Molecular and Cell Biology</i> , 1994 , 9, 263-282		4
23	Innovations in avoiding particle clearance from blood by Kupffer cells: cause for reflection. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 1994 , 11, 31-59	2.8	33
22	Current progress and future prospects of liposomes in dermal drug delivery. <i>Journal of Microencapsulation</i> , 1993 , 10, 155-62	3.4	16
21	An investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1993 , 1157, 233-40	4	122
20	Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1993 , 1179, 157-65	4.9	203
19	Effect of splenic congestion associated with haemolytic anaemia on filtration of 'spleen-homing' microspheres. <i>Clinical Science</i> , 1993 , 84, 605-9	6.5	15
18	Serum factors that regulate phagocytosis of liposomes by Kupffer cells. <i>Biochemical Society Transactions</i> , 1993 , 21, 128S	5.1	23
17	Enhanced hepatic clearance of intravenously administered sterically stabilized microspheres in zymosan-stimulated rats. <i>Journal of Leukocyte Biology</i> , 1993 , 54, 513-7	6.5	41
16	Microspheres for targeting drugs to specific body sites. <i>Journal of Controlled Release</i> , 1993 , 24, 157-163	11.7	80
15	Opsonophagocytosis of liposomes by peritoneal macrophages and bone marrow reticuloendothelial cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1992 , 1135, 269-74	4.9	48
14	The polyoxyethylene/polyoxypropylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. <i>FEBS Letters</i> , 1992 , 305, 62-6	3.8	136
13	Differences in the molecular weight profile of poloxamer 407 affect its ability to redirect intravenously administered colloids to the bone marrow. <i>International Journal of Pharmaceutics</i> , 1992 , 83, 273-276	6.5	20
12	The effect of block co-polymers on the uptake of model polystyrene microspheres by Kupffer cells--in vitro and in vivo studies. <i>Biochemical Society Transactions</i> , 1991 , 19, 329S	5.1	18
11	The effect of poloxamer-407 on liposome stability and targeting to bone marrow: comparison with polystyrene microspheres. <i>International Journal of Pharmaceutics</i> , 1991 , 68, 121-126	6.5	49
10	Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. <i>Biochemical and Biophysical Research Communications</i> , 1991 , 177, 861-6	3.4	248

9	Calcium as a possible modulator of Kupffer cell phagocytic function by regulating liver-specific opsonic activity. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1990 , 1028, 304-8	3.8	18
8	Physiopathological and physicochemical considerations in targeting of colloids and drug carriers to the bone marrow. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 1990 , 7, 187-209	2.8	5
7	Tissue Specific Serum Opsonins and Phagocytosis of Liposomes 1990 , 87-94		3
6	Differential properties of organ-specific serum opsonins for liver and spleen macrophages. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1989 , 984, 379-83	3.8	75
5	Serum opsonins and phagocytosis of saturated and unsaturated phospholipid liposomes. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1989 , 984, 384-7	3.8	100
4	Tissue specific opsonins for phagocytic cells and their different affinity for cholesterol-rich liposomes. <i>FEBS Letters</i> , 1988 , 233, 143-7	3.8	119
3	The diagnostic potential of microneedles in infectious diseases. <i>Precision Nanomedicine</i> ,	1.2	2
2	The Role of Complement in Antibody Therapy for Infectious Diseases63-74		
1	The Innate Immune Responses, Adjuvants and Delivery Systems113-127		4